AbbVie

1367 articles with AbbVie

• 

  Texas Goes After Pharmas for Alleged Use of Hormone Drugs to Treat Gender Dysphoria

  12/14/2021

  Texas’ top law enforcement official is taking aim at two drug companies over what he alleges is the promotion of hormone blockers for children experiencing gender dysphoria.

• FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults

  12/13/2021

  Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia).

• SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

  12/10/2021

  SpringWorks Therapeutics, Inc. today announced that the company has entered into a clinical trial collaboration agreement with AbbVie, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor.

• 

  Former Scripps and Humira Leader Richard Lerner Passes Away

  12/7/2021

  Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.

• Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

  12/6/2021

  AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remissiona,b and endoscopic responsec at week 12.1.

• 

  New FDA Safety Warning Potentially Bad News for JAK Market

  12/6/2021

  The regulatory agency just placed new safety warnings on that drug class, which will impact AbbVie's Rinvoq (upadacitinib), a drug the company has seen as a successor to its revenue-driving Humira.

• AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.

  12/3/2021

  AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ ® (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

• AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)

  11/30/2021

  AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI®.

• AbbVie to Present at the Evercore ISI Conference - Nov 23, 2021

  11/23/2021

  AbbVie will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021.

• AbbVie to Present at the Piper Sandler Healthcare Conference

  11/23/2021

   AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021.

• Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting

  11/19/2021

  Allergan Aesthetics, an AbbVie company, (NYSE: ABBV) today announced that it will present six abstracts from its leading portfolio of aesthetic treatments and products at the American Society for Dermatologic Surgery (ASDS) meeting taking place virtually November 19-21, 2021.

• New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission

  11/18/2021

  AbbVie announced the publication of results from a new literature review in Advances in Therapy.

• AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis

  11/17/2021

  AbbVie announced that the European Commission has approved SKYRIZI® alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs.

• 

  Warren Buffet Scales Back Big Biopharma Investments

  11/17/2021

  This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck. 
• 

  Clinical Catch-Up: November 8-12

  11/15/2021

  It was another busy week for clinical trial news. Here’s a look.

• AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

  11/10/2021

  AbbVie (NYSE: ABBV) and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research.

• AbbVie to Present at the Wolfe Research Healthcare Conference - Nov 10, 2021

  11/10/2021

  AbbVie will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021.

• AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021

  11/9/2021

  AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021

• AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

  11/9/2021

  AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

• 

  Oklahoma’s Highest Court Overturns Landmark Opioid Verdict Against J&J

  11/9/2021

  The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.